Cure-Related Research Resources
A resource listing of articles, reports, websites, and ongoing clinical trials related to the research effort to cure HIV infection.
Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa
An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.
An Activist’s Guide to the LAM Test
Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced…
Treatment Action Group Statement on the HVTN 702 HIV Vaccine Trial Results
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.
Good COPs or Bad COPs: Promoting Interventions for Coinfections and AIDS in 2020 PEPFAR Country Operational Plans (COPs)
On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
Sanofi Withdraws Two Patent Applications on Life-Saving Tuberculosis Prevention Drugs in Europe and in Indonesia
Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.
HIV & Aging
A resource listing of articles, reports, websites, and ongoing clinical trials related to HIV and aging.
2019 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.
Treatment Action Group Applauds Indian TB Activists in Opposing Patents for Critical TB Prevention Drugs
Treatment Action Group (TAG) applauds the legal actions undertaken by our colleagues from the Delhi Network of Positive People (DNP+) and tuberculosis (TB) survivor and activist Ganesh Acharya of Mumbai, with support from the Third World Network (TWN), contesting two patent applications on combinations of two decades-old TB medicines filed in India by French pharmaceutical company Sanofi.
Clinical Trials for People with Suboptimal Immune Reconstitution Despite HIV Suppression
Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.